Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTX 474

Next Previous
X
Search
Drug Profile

MTX 474

Alternative Names: MTX-474

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mediar Therapeutics
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Ephrin-B2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibrosis

Most Recent Events

  • 10 Jul 2024 Phase-I clinical trials in Fibrosis (In volunteers, In adults) in Australia (Parenteral) (NCT06535841)
  • 06 May 2024 Mediar Therapeutics plans a phase I trial for fibrosis in Q3 2024 (Parenteral)
  • 01 Nov 2023 Preclinical trials in Fibrosis in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top